In addition, the similar kidney outcome irrespective of C3 deposition, as it is suggested in some studies [107], does not justify the use of complement fractions as specific biomarkers of ANCA-vasculitis outcomes, at least at present. This evidence concerns the gene C3 and vasculitis.